STOCK TITAN
  1. Home
  2. Financials
  3. IPHYF
  4. Revenue

Innate Pharma (IPHYF) Revenue by Year

IPHYF OTC

Innate Pharma generated $10.6M in revenue in fiscal year 2025. This represents a decrease of 49.3% from the prior fiscal year. The table below carries 9 fiscal years, from 2017 to 2025.

FY2025 annual
Revenue $10.6M
YoY -49.3%
5Y CAGR -34.1%
Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

IPHYF Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Revenue$10.6M-49.3%$20.8M-69.5%$68.2M+10.5%$61.7M+120.7%$28.0M-67.2%$85.3M-11.1%$95.9M-10.9%$107.6M+103.3%$52.9M

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Innate Pharma financials

Frequently Asked Questions

Innate Pharma generated $10.6M in revenue in fiscal year 2025.

Innate Pharma (IPHYF) revenue fell by 49.3% year over year, from $20.8M to $10.6M in fiscal year 2025.

Across the 9 fiscal years this page covers, Innate Pharma (IPHYF) revenue went from $52.9M in fiscal year 2017 to $10.6M in fiscal year 2025.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Innate Pharma (IPHYF) reported on that line in every period on record.